Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**darexaban + digoxin** is a combination of two pharmaceuticals: darexaban, an oral direct Factor Xa inhibitor (anticoagulant), and digoxin, a cardiac glycoside most commonly used for the management of heart failure and atrial fibrillation. Darexaban acts by selective inhibition of Factor Xa, interrupting the coagulation cascade and thus preventing thrombosis. Digoxin increases cardiac contractility and inhibits atrioventricular conduction through inhibition of Na+/K+-ATPase and enhancement of vagal tone. Co-administration in studies primarily evaluated pharmacokinetic interaction, with evidence showing no clinically significant pharmacokinetic interaction between darexaban (in modified-release form) and digoxin in healthy subjects[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on darexaban + digoxin.